US Edition10x Genomics to Acquire Scale Biosciences
PLEASANTON, CALIFORNIA, AUG 7 – The acquisition will enhance 10x Genomics' Chromium platform and increase accessibility to scalable single cell analysis, supporting initiatives like the 100 Million Cell Challenge.
- Yesterday, Scale Biosciences confirmed its acquisition by 10x Genomics, Inc. in Pleasanton, Calif., under a definitive agreement announced Aug. 7, 2025, and Garry Nolan said, `These inventions were designed to make single cell analysis dramatically more scalable and accessible.'
- 10x is bolstering its commitment to scale single cell experiments through the acquisition, which provides inventions to advance its Chromium platform and is expected to enhance the accessibility of single cell analysis.
- Alongside financial terms, Giovanna Prout said the integration will accelerate adoption and support a broader global customer base.
- Garry Nolan noted that Scale's inventions will become more scalable, reflecting the deal's strategic vision, as Serge Saxonov emphasized 10x's commitment to continued innovation.
- Future projections show the combined technologies are poised to fuel breakthroughs in oncology, immunology, and neuroscience while supporting the 100 Million Cell Challenge, CZI’s Billion Cell Project, and the Virtual Cell Atlas.
Insights by Ground AI
Does this summary seem wrong?
19 Articles
19 Articles
10x Genomics Scales Up, Agrees to Acquire Scale Biosciences
10x Genomics is bolstering its commitment to scaling single cell experiments through the acquisition of Scale Biosciences. 10x has agreed to pay $30 million in cash and stock upfront, plus an undisclosed amount in additional payments tied to achieving milestones, Serge Saxonov, PhD, CEO of 10x, told GEN in an exclusive interview. Scale’s technology, and the company, will be integrated into 10x. “I was excited from the first mention of the deal,”…
Coverage Details
Total News Sources19
Leaning Left1Leaning Right0Center8Last UpdatedBias Distribution89% Center
Bias Distribution
- 89% of the sources are Center
89% Center
11%
C 89%
Factuality
To view factuality data please Upgrade to Premium
